Sharechat Logo

AFT Pharmaceuticals Limited (NZX: AFT) Appoints McPherson's as Singapore Distributor

Friday 5th November 2021

Text too small?

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has signed an exclusive distribution agreement with ASX-listed McPherson’s Limited (ASX: MCP) to drive growth of its over the counter (OTC) products in Singapore.

The move is aimed at maximising the potential for AFT’s medicines in Singapore, where the OTC market is worth approximately $US600 million and is forecast to grow at around 5.45% to reach $US800 million by 2026*. It is also part of AFT’s broader strategy to grow its presence in Asia.

McPherson’s will distribute and market the tablet form of AFT’s patented Maxigesic pain relief medicine, launched in Singapore in 2018, AFT’s premium Liposomal Nutritional Supplements as well as a number of other newly registered pharmaceuticals.

The agreement seeks to leverage McPherson’s experienced sales and marketing teams in Singapore and will ensure channel strategies and product and merchandising activations are tailored to the local market.

AFT Pharmaceuticals Chief Executive Dr Hartley Atkinson said: “This partnership affirms AFT’s commitment to building new categories and distribution in existing Asian markets and further reaching out into the region.

“We are very pleased with the progress we have made in Singapore, but this agreement with McPherson’s, a specialist OTC distributor, ensures we are aligned with the right partners to ensure success in the future”.

McPherson’s Chief Executive Officer, Grant Peck said “We believe our established distribution channels and strong sales team in Singapore are a great fit for AFT and we are excited for what this partnership will achieve together. AFT’s OTC product brands have great synergies with McPherson’s focus in the health category and we are committed to market growth.”

Please see the link below for details

AFT appoints McPherson’s as Singapore distributor

Source: AFT Pharmaceuticals Limited



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

GSH Appointment of new Chairman
Greenfern secures agreement to supply medicinal cannabis
Rua on track to export to Germany by year end
HMY SECURES ADDITIONAL NZ$215M FACILITY TO SUPPORT GROWTH
Seeka releases Sustainability Report
NZL - Completion of Retail Offer
28th June 2022 Morning Report
Green Cross Health Limited 2022 Annual Report / NOM
Me Today completes Rights Issue
Channel confirms timing of Board Chair succession